Show simple item record

dc.contributor.authorPécoul, B
dc.contributor.authorChirac, P
dc.contributor.authorTrouiller, P
dc.contributor.authorPinel, J
dc.date.accessioned2008-02-21T17:06:33Z
dc.date.available2008-02-21T17:06:33Z
dc.date.issued1999-01-27
dc.identifier.citationAccess to Essential Drugs in Poor Countries: A Lost Battle? 1999, 281 (4):361-7 JAMAen
dc.identifier.issn0098-7484
dc.identifier.pmid9929090
dc.identifier.urihttp://hdl.handle.net/10144/18924
dc.descriptionTo access this article, click on "Additional Links"
dc.description.abstractDrugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis. Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs. These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.
dc.language.isoenen
dc.relation.urlhttp://jama.ama-assn.org/cgi/content/full/281/4/361?ijkey=v7ANi6A7kiVu2&keytype=ref&siteid=amajnls
dc.rightsArchived with thanks to the American Medical Associationen
dc.subject.meshDeveloping Countriesen
dc.subject.meshDrug Industryen
dc.subject.meshDrug Utilizationen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshInternational Agenciesen
dc.subject.meshInternational Cooperationen
dc.subject.meshPharmaceutical Preparationsen
dc.subject.meshQuality Controlen
dc.titleAccess to Essential Drugs in Poor Countries: A Lost Battle?en
dc.contributor.departmentFondation Médecins Sans Frontières, Paris, France. office@paris.msf.orgen
dc.identifier.journalJAMA : the Journal of the American Medical Associationen
html.description.abstractDrugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis. Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs. These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.


This item appears in the following Collection(s)

Show simple item record